About Juniper Pharmaceuticals
Juniper Pharmaceuticals, Inc., formerly Columbia Laboratories, Inc., is a women's health therapeutic company focused on developing intra-vaginal therapeutics that addresses the medical needs in women's health. The Company operates through two segments: product and service. The product segment includes supply chain management for CRINONE. The product segment also includes the royalty stream the Company receives from Allergan for CRINONE sales in the United States, as well as the development of new product candidates. The service segment includes pharmaceutical development, clinical trial manufacturing and advanced analytical and consulting services for the its customers, as well as characterizing and developing pharmaceutical product candidates for its internal programs, and managing the preclinical and clinical manufacturing of COL-1077 and its intra-vaginal ring (IVR). Its product and product development programs include CRINONE 8%, COL-1077, JNP-0101, JNP-0101 and JNP-0301.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: JNP
- Previous Close: $4.80
- 50 Day Moving Average: $5.19
- 200 Day Moving Average: $5.57
- 52-Week Range: $4.30 - $8.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -48.00
- P/E Growth: 0.00
- Market Cap: $52.05M
- Outstanding Shares: 10,843,000
- Beta: 0.25
- Net Margins: -7.44%
- Return on Equity: -9.68%
- Return on Assets: -6.47%
Companies Related to Juniper Pharmaceuticals:
- Debt-to-Equity Ratio: 0.08%
- Current Ratio: 1.73%
- Quick Ratio: 1.42%
What is Juniper Pharmaceuticals' stock symbol?
Juniper Pharmaceuticals trades on the NASDAQ under the ticker symbol "JNP."
Where is Juniper Pharmaceuticals' stock going? Where will Juniper Pharmaceuticals' stock price be in 2017?
3 brokers have issued twelve-month target prices for Juniper Pharmaceuticals' shares. Their forecasts range from $6.75 to $16.50. On average, they anticipate Juniper Pharmaceuticals' stock price to reach $11.63 in the next year.
When will Juniper Pharmaceuticals announce their earnings?
Juniper Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.
Who owns Juniper Pharmaceuticals stock?
Juniper Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include JW Asset Management LLC (3.03%), Renaissance Technologies LLC (2.35%), Stonepine Capital Management LLC (2.11%), Dimensional Fund Advisors LP (0.66%), Gabelli Funds LLC (0.60%) and GSA Capital Partners LLP (0.19%). Company insiders that own Juniper Pharmaceuticals stock include Alicia Secor, C Ann Merrifield, Frank Condella Jr, Frank M Armstrong, George Elston, James A Geraghty and Nikin Patel.
Who sold Juniper Pharmaceuticals stock? Who is selling Juniper Pharmaceuticals stock?
Juniper Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP.
Who bought Juniper Pharmaceuticals stock? Who is buying Juniper Pharmaceuticals stock?
Juniper Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Renaissance Technologies LLC and JW Asset Management LLC. Company insiders that have bought Juniper Pharmaceuticals stock in the last two years include Alicia Secor, C Ann Merrifield, Frank Condella Jr, Frank M Armstrong, George Elston, James A Geraghty and Nikin Patel.
How do I buy Juniper Pharmaceuticals stock?
Shares of Juniper Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Juniper Pharmaceuticals stock cost?
One share of Juniper Pharmaceuticals stock can currently be purchased for approximately $4.80.